ArriVent BioPharma, Inc.

A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.

AVBP | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 18 CAMPUS BLVD., NEWTOWN SQUARE
Website:: https://arrivent.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy centers on forging strategic partnerships to in-license and accelerate the global development of promising drug candidates. Its pipeline is led by its lead development candidate, firmonertinib, an investigational cancer therapeutic, and includes other novel oncology treatments such as next-generation antibody-drug conjugates. ArriVent leverages its team's extensive drug development and regulatory expertise to advance its portfolio and address significant unmet medical needs for global patient populations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ArriVent BioPharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ArriVent BioPharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ArriVent BioPharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Atea Pharmaceuticals, Inc. A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.	United States of America	AVIR
Athira Pharma, Inc. Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.	United States of America	ATHA
ATOSSA THERAPEUTICS, INC. Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.	United States of America	ATOS
ATUM CO., LTD. Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.	South Korea	355690
aTYR PHARMA INC Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.	United States of America	ATYR
Aura Biosciences, Inc. Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.	United States of America	AURA
Aurinia Pharmaceuticals Inc. Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.	United States of America	AUPH
AURORA CANNABIS INC A global producer and seller of medical and recreational cannabis and derivative products.	United States of America	ACB
Autolus Therapeutics plc Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.	United States of America	AUTL
AVADEL PHARMACEUTICALS PLC Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.	United States of America	AVDL